Eating disorders Manufacturing Pharmaceuticals 
Psychiatric Times
JUNE 23, 2025
SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.
Psychiatric Times
JUNE 30, 2025
NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. A recently filed patent on its preservative-free manufacturing process may further support market exclusivity.
Mad in America
OCTOBER 18, 2023
For the pharmaceutical industry, the bigger and wider those diseases, the more people who can be diagnosed, and the bigger your markets are. The marketing of medical conditions has become a key plank of pharmaceutical industry marketing. Helping widen the definitions of disease is a key part of marketing those pharmaceutical products.
Expert insights. Personalized for you.
Let's personalize your content